A phase III study to evaluate immune non inferiority and safety of the All in One liquid formulation of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine (BRV-TV) to a licensed vaccine RotaTeq when administered as three dose series to Indian infants concomitantly with other routinely recommended vaccines for the age.

Trial Profile

A phase III study to evaluate immune non inferiority and safety of the All in One liquid formulation of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine (BRV-TV) to a licensed vaccine RotaTeq when administered as three dose series to Indian infants concomitantly with other routinely recommended vaccines for the age.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Bovine rotavirus vaccine reassortant (Primary) ; Rotavirus vaccine
  • Indications Rotavirus infections
  • Focus Therapeutic Use
  • Sponsors Shantha Biotechnics
  • Most Recent Events

    • 22 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top